{"id":"cisplatin-navelbine-radiotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"10-20%","effect":"Anemia"},{"rate":"5-15%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cisplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, leading to DNA damage and apoptosis. Navelbine, also known as vinorelbine, is a vinca alkaloid that binds to tubulin, preventing microtubule formation and thereby inhibiting cell division. This combination therapy is used to treat various types of cancer.","oneSentence":"Cisplatin works by crosslinking DNA, causing cell death, while Navelbine inhibits microtubule formation, disrupting cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:55.421Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, Small cell lung cancer, Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT04648033","phase":"PHASE1","title":"Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-12-07","conditions":"Locally Advanced Non-Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT04765709","phase":"PHASE2","title":"Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-09-24","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":10},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT00354393","phase":"PHASE2","title":"Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2002-08","conditions":"Malignant Mesothelioma","enrollment":9},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":"Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy","enrollment":29},{"nctId":"NCT02974426","phase":"PHASE3","title":"To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Shanghai Chest Hospital","startDate":"2016-11","conditions":"Non-small Cell Lung Cancer Stage IIIA, Radiotherapy","enrollment":132},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT02465736","phase":"PHASE3","title":"Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-07","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Oesophageal Cancer","enrollment":610},{"nctId":"NCT02709720","phase":"PHASE2","title":"Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2016-04-15","conditions":"Lung Cancer","enrollment":68},{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":"Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms","enrollment":36},{"nctId":"NCT01118676","phase":"PHASE1","title":"Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2010-03","conditions":"Locally Advanced Non Small Cell Lung Cancer (NSCLC)","enrollment":14},{"nctId":"NCT00302003","phase":"PHASE3","title":"Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-02","conditions":"Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma","enrollment":287},{"nctId":"NCT03986463","phase":"","title":"CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-01","conditions":"Lung Neoplasms, Lung Cancer, Neoplasm of Lung","enrollment":40},{"nctId":"NCT02977169","phase":"PHASE2","title":"To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2016-11","conditions":"Non-small Cell Lung Cancer Stage IIIA, Radiotherapy","enrollment":300},{"nctId":"NCT00198367","phase":"PHASE2","title":"Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2003-01","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT01029678","phase":"PHASE2","title":"Concomitant Radio-chemotherapy in the Elderly","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2010-01","conditions":"Non Small Cell Lung Cancer","enrollment":48},{"nctId":"NCT00985855","phase":"PHASE2","title":"Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Institut de Cancérologie de la Loire","startDate":"2009-09","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":91},{"nctId":"NCT00455572","phase":"PHASE1","title":"Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-05-11","conditions":"Lung Cancer, Non-Small Cell","enrollment":71},{"nctId":"NCT01216527","phase":"PHASE3","title":"Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2007-06","conditions":"Squamous Cell Esophageal Carcinoma","enrollment":430},{"nctId":"NCT00683514","phase":"PHASE3","title":"Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2005-04","conditions":"NSCLC","enrollment":201},{"nctId":"NCT00686959","phase":"PHASE3","title":"Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-09","conditions":"Non Small Cell Lung Cancer","enrollment":598},{"nctId":"NCT02720614","phase":"PHASE2","title":"Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"LIN QIANG","startDate":"2012-05","conditions":"Non-small Cell Lung Cancer","enrollment":12},{"nctId":"NCT00675597","phase":"NA","title":"Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-05","conditions":"Lung Cancer","enrollment":25},{"nctId":"NCT00661011","phase":"PHASE2","title":"Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy","status":"TERMINATED","sponsor":"European Lung Cancer Working Party","startDate":"2007-01","conditions":"Non Small Cell Lung Carcinoma","enrollment":75},{"nctId":"NCT01664663","phase":"PHASE2","title":"Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy","status":"TERMINATED","sponsor":"Ass. Prof. Jan Nyman","startDate":"2011-09","conditions":"Non Small Cell Lung Cancer, Locally Advanced Disease","enrollment":37},{"nctId":"NCT00309972","phase":"PHASE3","title":"Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"University College, London","startDate":"2005-12","conditions":"Lung Cancer","enrollment":130},{"nctId":"NCT00193921","phase":"PHASE2","title":"Chemoradiotherapy in Patients With Localised Lung Cancer","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2003-02","conditions":"Non Small Cell Lung Carcinoma","enrollment":82},{"nctId":"NCT00253591","phase":"PHASE2, PHASE3","title":"Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"2005-06","conditions":"Lung Cancer","enrollment":500},{"nctId":"NCT00003240","phase":"PHASE3","title":"Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute (NCI)","startDate":"1995-10","conditions":"Lung Cancer","enrollment":1800},{"nctId":"NCT00055887","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2002-11","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT01839032","phase":"PHASE2","title":"Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2005-05","conditions":"Lung Cancer","enrollment":70},{"nctId":"NCT00002823","phase":"PHASE3","title":"Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"1995-02","conditions":"Lung Cancer","enrollment":3300},{"nctId":"NCT00005838","phase":"PHASE3","title":"Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-03","conditions":"Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer","enrollment":756},{"nctId":"NCT01124812","phase":"PHASE1","title":"131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Philogen S.p.A.","startDate":"2010-05","conditions":"Non Small Cell Lung Cancer","enrollment":3},{"nctId":"NCT01687439","phase":"PHASE2","title":"Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2008-12","conditions":"Non-small Cell Lung Cancer","enrollment":15},{"nctId":"NCT00522886","phase":"PHASE1","title":"Phase I Cetuximab and Concurrent Radio-chemotherapy","status":"COMPLETED","sponsor":"Maastricht Radiation Oncology","startDate":"2007-04","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT01203735","phase":"PHASE1, PHASE2","title":"Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2011-02","conditions":"Locally Advanced Inoperable Non-small-lung Cancer","enrollment":20},{"nctId":"NCT00083083","phase":"PHASE2","title":"Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"American College of Radiology Imaging Network","startDate":"2005-03","conditions":"Lung Cancer","enrollment":250},{"nctId":"NCT00295672","phase":"PHASE2","title":"Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2006-02","conditions":"Lung Neoplasm","enrollment":60},{"nctId":"NCT00333294","phase":"PHASE2","title":"Phase II Iressa + Irradiation Followed by Chemo in NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Non-Small Cell Lung Cancer","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cisplatin-Navelbine-Radiotherapy","genericName":"Cisplatin-Navelbine-Radiotherapy","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin works by crosslinking DNA, causing cell death, while Navelbine inhibits microtubule formation, disrupting cell division. Used for Non-small cell lung cancer, Small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}